Dimensions of Outcome with Clozapine
- 1 May 1992
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 160 (S17), 46-53
- https://doi.org/10.1192/s000712500029692x
Abstract
Various outcome measures following clozapine administration to neuroleptic-resistant schizophrenic patients are considered. The importance of a multidimensional perspective is emphasised. There was significant improvement in positive symptoms, some negative symptoms, quality of life, some types of cognitive function (e.g. semantic memory), extrapyramidal function, and tardive dyskinesia. Readmission to hospital, and family burden were markedly reduced, which achieved significant savings in the cost of treatment. Compliance with clozapine and weekly blood testing can be achieved in the majority of treatment-resistant cases. These benefits may occur independently of each other.Keywords
This publication has 38 references indexed in Scilit:
- Prevalence and severity of akathisia in patients on clozapineBiological Psychiatry, 1991
- Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.Journal of Abnormal Psychology, 1989
- Leponex ? associated granulocytopenia: a review of the situationPsychopharmacology, 1989
- The effect of long‐term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 yearsActa Psychiatrica Scandinavica, 1988
- Reliability and validity of the positive and negative syndrome scale for schizophrenicsPsychiatry Research, 1988
- Tolerability and therapeutic effect of clozapineActa Psychiatrica Scandinavica, 1985
- Effect of Clozapine in Severe Tardive DyskinesiaJournal of Clinical Psychopharmacology, 1984
- Schizophrenia and brain dysfunction: An integration of recent neurodiagnostic findings.Psychological Bulletin, 1983
- Molecular pathology of schizophrenia: more than one disease process?BMJ, 1980